ATE437653T1 - Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika - Google Patents

Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika

Info

Publication number
ATE437653T1
ATE437653T1 AT04753672T AT04753672T ATE437653T1 AT E437653 T1 ATE437653 T1 AT E437653T1 AT 04753672 T AT04753672 T AT 04753672T AT 04753672 T AT04753672 T AT 04753672T AT E437653 T1 ATE437653 T1 AT E437653T1
Authority
AT
Austria
Prior art keywords
dose
antimitotics
combination
treated
antimitotic
Prior art date
Application number
AT04753672T
Other languages
English (en)
Inventor
Robert Johnson
Yiqing Zhou
Thomas Mueller
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Application granted granted Critical
Publication of ATE437653T1 publication Critical patent/ATE437653T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04753672T 2003-05-30 2004-05-28 Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika ATE437653T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47490603P 2003-05-30 2003-05-30
US10/856,742 US7691838B2 (en) 2003-05-30 2004-05-27 Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
PCT/US2004/016888 WO2005000314A1 (en) 2003-05-30 2004-05-28 Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics

Publications (1)

Publication Number Publication Date
ATE437653T1 true ATE437653T1 (de) 2009-08-15

Family

ID=33555375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04753672T ATE437653T1 (de) 2003-05-30 2004-05-28 Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika

Country Status (6)

Country Link
US (1) US7691838B2 (de)
EP (1) EP1628667B1 (de)
AT (1) ATE437653T1 (de)
DE (1) DE602004022285D1 (de)
ES (1) ES2329134T3 (de)
WO (1) WO2005000314A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
WO2004089304A2 (en) * 2003-04-01 2004-10-21 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
RS52642B (sr) * 2004-11-18 2013-06-28 Synta Pharmaceuticals Corp. Jedinjenja triazola koja modulišu aktivnost hsp90
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
JP4956737B2 (ja) * 2005-02-23 2012-06-20 国立大学法人名古屋大学 抗ポリグルタミン病剤
JP5118039B2 (ja) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
WO2007041294A2 (en) * 2005-09-29 2007-04-12 The Trustees Of Boston University Methods for sensitizing cancer cells to inhibitors
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
EP2032545A2 (de) * 2006-05-25 2009-03-11 Synta Pharmaceuticals Corporation Verbindungen als modulatoren der hsp90-aktivität und verfahren für ihre identifizierung
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US20160223547A1 (en) * 2013-09-13 2016-08-04 Angels SIERRA JIMÉNLEZ Marker for predicting metastasis of breast cancer
KR20160015076A (ko) 2014-07-30 2016-02-12 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 Hsp90
CN105497034B (zh) * 2015-12-08 2018-08-07 暨南大学 一种通过靶向prmt5抑制骨肉瘤生长的组合物及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
DE69329073T2 (de) * 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5977163A (en) 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE19744676A1 (de) 1997-10-10 1999-04-15 Forschungszentrum Borstel Zent Kombinationspräparate für die Therapie von Tumoren
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
CA2373994A1 (en) 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9918429D0 (en) 1999-08-04 1999-10-06 Novartis Ag Organic compounds
DZ3223A1 (fr) * 1999-10-19 2001-04-26 Merck & Co Inc Inhibiteurs de tyrosine kinases
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE526019T1 (de) 2000-07-28 2011-10-15 Sloan Kettering Inst Cancer Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
AU2001280105A1 (en) 2000-08-22 2002-03-04 Kyowa Hakko Kogyo Co. Ltd. Methof of regulating apoptosis and apoptosis-regulatory polypeptide
AU2001296558A1 (en) * 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2877202A (en) 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
DE60213386T2 (de) * 2001-03-30 2006-11-23 The United States Of America Represented By The Secretary, Department Of Health And Human Services Geldanamycinderivate zur krebsbehandlung
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP2336133A1 (de) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purinanaloga mit HSP90-inhibierender Wirkung
EP1450784A4 (de) * 2001-11-09 2005-02-09 Conforma Therapeutics Corp Hsp90-hemmende zearalanol-verbindungen und verfahren zu ihrer herstellung und verwendung
WO2003050295A2 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0207362D0 (en) 2002-03-28 2002-05-08 Univ Liverpool Chemotherapy
JP2005528390A (ja) 2002-04-10 2005-09-22 コンフォーマ・セラピューティクス・コーポレイション アンサマイシン製剤およびその製造ならびに使用方法
AU2003303058A1 (en) 2002-12-12 2004-07-09 Conforma Therapeutics Corporation Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis

Also Published As

Publication number Publication date
US7691838B2 (en) 2010-04-06
EP1628667B1 (de) 2009-07-29
DE602004022285D1 (de) 2009-09-10
EP1628667A1 (de) 2006-03-01
ES2329134T3 (es) 2009-11-23
WO2005000314A1 (en) 2005-01-06
US20050020558A1 (en) 2005-01-27
EP1628667A4 (de) 2007-04-04

Similar Documents

Publication Publication Date Title
ATE437653T1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
ATE382346T1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
WO2005000213A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
WO2005000211A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
WO2005000212A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
MY151032A (en) Treatment of tnf? related disorders
TW200507833A (en) Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
WO2004030625A3 (en) Synergistic methods and compositions for treating cancer
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
MY138732A (en) Conjugated complement cascade inhibitors
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
WO2005000214A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
EA200501166A1 (ru) Составы и способы лечения тромбоцитемии
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
DE60231896D1 (de) Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties